Nasus Pharma is trading 6.63% down at $3.10 after falling from the August 5 close of $3.32, with no clear catalyst identified.
- Searches found no new company-specific announcement on August 6, 2026.
- The latest material disclosure was the July 28 appointment of Brendan P. O’Grady as CEO, succeeding Dan Teleman; it is not a clear explanation for today’s decline.
- Healthcare is stronger, while major indexes are mixed.